#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Prostate cancer Obesity Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Malignant melanoma Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Amyotrophic lateral sclerosis gene carrier Exudative retinopathy Cardiac sarcoidosis Myeloid leukaemia Primary amyloidosis Hidradenitis Fusarium infection Encephalitis autoimmune Thromboangiitis obliterans Oesophageal squamous cell carcinoma stage II Dupuytren's contracture Transitional cell carcinoma Peritoneal neoplasm Osteochondrodysplasia More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Basic Information Nephroblastoma – Diagnostics Prader-Willi syndrome – Treatment Mucopolysaccharidosis Sarcoma – Life with Disease Ewing’s sarcoma metastatic – Life with Disease Hereditary neuropathic amyloidosis – Life with Disease Primary biliary cholangitis – Basic Information Synovial sarcoma recurrent – Life with Disease Activated PI3 kinase delta syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Talquetamab Tamoxifen Clobetasol Glepaglutide Cefuroxime Human Serum Albumin 5% Anb032 Carbetocin Omeprazole Bexotegrast Mosaic Hbcoreag Amsacrine Polatuzumab Vedotin ULTEVURSEN CICLOPIROX Tetracaine Hydrochloride Mepacrine Regn7257 YOHIMBINE HYDROCHLORIDE Amb-05X More therapies…

    Learn about Your Condition

    Oesophageal atresia Marfan's syndrome Hepatitis D Colon cancer stage IV Chorioretinitis Immune-mediated renal disorder Lymphangioleiomyomatosis Trisomy 21 Ophthalmoplegia Haemorrhage Short-bowel syndrome Metastatic gastric cancer Progressive multiple sclerosis Skin papilloma Medulloblastoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Klinički bolnički centar Zagreb (University Hospital…

Klinički bolnički centar Zagreb (University Hospital Center Zagreb)

Vinogradska Cesta 29, Zagreb, Zagreb, 10000, Croatia

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    • Belzutifan
    • Cabozantinib
    Austria Belgium Croatia Czechia Denmark France +6

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Diseases:
    • Secondary progressive multiple sclerosis
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Fexofenadine
    • Felzartamab
    • Loratadine
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

    Recruiting

    3 1
    Investigated Diseases:
    • Bronchiectasis
    Investigated Drugs:
    • Bi 1291583
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists

    Recruiting

    3 1
    Investigated Drugs:
    • Finerenone
    Croatia Czechia Greece Hungary Italy Poland +1

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Abiraterone
    • Apalutamide
    • Darolutamide
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study on Sotagliflozin for Improving Symptoms in Patients with Hypertrophic Cardiomyopathy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Sotagliflozin
    Belgium Bulgaria Croatia Czechia France Germany +7

  • Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Vedolizumab
    • Upadacitinib
    Austria Belgium Croatia Czechia Denmark France +12

  • Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

    Recruiting

    2 1
    Investigated Diseases:
    • Partial seizures
    Investigated Drugs:
    • Bhv-7000
    Austria Belgium Croatia Czechia France Hungary +3

  • Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    • Petosemtamab
    Austria Belgium Croatia Czechia France Germany +8
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!